US EditionPfizer in $41.5 million settlement with Texas over ADHD drug for children
The $41.5 million settlement resolves allegations that Pfizer and Tris Pharma manipulated testing of Quillivant XR, an ADHD drug often failing to dissolve, defrauding Texas Medicaid.
- On Wednesday, Pfizer and supplier Tris Pharma agreed to a $41.5 million settlement with Texas to resolve claims they defrauded the Texas Medicaid program, Texas Attorney General Ken Paxton said.
- A whistleblower complaint by Tarik Ahmed, former Tris technology chief , alleges the suit claims Tris Pharma altered testing methods between 2012 and 2018 for Quillivant XR.
- The lawsuit contends Pfizer misrepresented to state Medicaid officials that Quillivant XR was properly manufactured and complied with federal and state law, and Texas Attorney General Ken Paxton alleged violations of the Texas Health Care Program Fraud Prevention Act.
- Paxton said many families complained the medicine did not work for children on Medicaid, and Tris Pharma manufactured Quillivant for Pfizer until 2018; Paxton is running for the U.S. Senate 2026 campaign against Senator John Cornyn.
- Pfizer denied wrongdoing in agreeing to settle and said its review found no patient-safety impact, while Tris Pharma and Paxton’s office did not immediately respond to requests for comment.
15 Articles
15 Articles
Pfizer will pay $41.5 million to Texas to close a lawsuit for supplying children enrolled in a public health program with supposedly adulterated drugs, the state attorney said Wednesday.
Pfizer agreed to pay $41.5 million to the state of Texas to put an end to a lawsuit accusing it of providing children with a public health program with drugs allegedly adulterated, state attorney general Ken Paxton reported Wednesday, according to the AFP.]]>
Pfizer, Tris Pharma Reach $41.5 Million Settlement With Texas Over ADHD Drug
Texas Attorney General Ken Paxton on Nov. 19 announced that his office had reached a $41.5 million settlement with Pfizer and Tris Pharma to resolve a November 2023 lawsuit regarding the companies’ distribution of the attention deficit/hyperactivity disorder (ADHD) medication Quillivant to children. Paxton sued the pharmaceutical companies and Tris Pharma CEO Ketan Mehta, alleging that they knowingly provided adulterated Quillivant XR to Texas c…
Pfizer, Tris Pharma Settle For $41.5 Mn In Texas ADHD Drug Case
Texas's top prosecutor on Wednesday announced the state had reached a $41.5 million settlement with US drugmakers Pfizer and Tris Pharma, over allegations of drug adulteration and defrauding the state's Medicaid program.
Pfizer, Tris Pharma To Pay Texas $41.5 Million in ADHD Drug Suit
Pfizer Inc. and Tris Pharma Inc. will pay the state of Texas $41.5 million to settle claims that it allegedly provided adulterated drugs to treat minors for attention-deficit/hyperactivity disorder, Texas Attorney General Ken Paxton (R) announced Wednesday.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
